Evidence map›Paper›PMID 33104793›Full record

ArticleBlood advances2020

Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes.

Joseph H Oved, Daria V Babushok, Michele P Lambert, Nicole Wolfset, M Anna Kowalska, Mortimer Poncz, Konrad J Karczewski, Timothy S Olson

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Joseph H OvedDivision of Hematology, Department of Pediatrics.
Daria V BabushokComprehensive Bone Marrow Failure Center, Division of Hematology, and.
Michele P LambertDivision of Hematology, Department of Pediatrics.
Nicole WolfsetDepartment of Pediatrics, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE.
M Anna KowalskaDivision of Hematology, Department of Pediatrics.
Mortimer PonczDivision of Hematology, Department of Pediatrics.
Konrad J KarczewskiAnalytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA; and.
Timothy S OlsonComprehensive Bone Marrow Failure Center, Division of Hematology, and.
Pediatrics and Genetics · USChildren's Hospital of Philadelphia · USAlfred I. duPont Hospital for Children · USBroad Institute · USHospital of the University of Pennsylvania · US

Funding

Institutional Clinical and Translational Science AwardKL2TR001879 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MEAGHER, EMMA ANNE · 2016 to 2025
$13.7M
Biology and Application of Platelet-Delivered Factor VIIIR01HL132557 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI PONCZ, MORTIMER · 2016 to 2019
$2.3M
Role of the Endothelium and Neutrophils in the Prothrombotic Nature of HITR01HL139448 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI PONCZ, MORTIMER · 2018 to 2020
$1.4M
Early Clonal Evolution in Acquired Aplastic AnemiaK08HL132101 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BABUSHOK, DARIA · 2016 to 2021
$992k
NCATS NIH HHS KL2 TR001879NHLBI NIH HHS K08 HL132101NHLBI NIH HHS R01 HL132557NHLBI NIH HHS R01 HL139448
6 · The paper itself

Abstract

Inherited bone marrow failure (IBMF) syndromes are rare blood disorders characterized by hematopoietic cell dysfunction and predisposition to hematologic malignancies. Despite advances in the understanding of molecular pathogenesis of these heterogeneous diseases, genetic variant interpretation, genotype-phenotype correlation, and outcome prognostication remain difficult. As new IBMF and other myelodysplastic syndrome (MDS) predisposition genes continue to be discovered (frequently in small kindred studies), there is an increasing need for a systematic framework to evaluate penetrance and prevalence of mutations in genes associated with IBMF phenotypes. To address this need, we analyzed population-based genomic data from >125 000 individuals in the Genome Aggregation Database for loss-of-function (LoF) variants in 100 genes associated with IBMF. LoF variants in genes associated with IBMF/MDS were present in 0.426% of individuals. Heterozygous LoF variants in genes in which haploinsufficiency is associated with IBMF/MDS were identified in 0.422% of the population; homozygous LoF variants associated with autosomal recessive IBMF/MDS diseases were identified in only .004% of the cohort. Using age distribution of LoF variants and 2 measures of mutational constraint, LOEUF ("loss-of-function observed/expected upper bound fraction") and pLI ("probability of being loss-of-function intolerance"), we evaluated the pathogenicity, tolerance, and age-related penetrance of LoF mutations in specific genes associated with IBMF syndromes. This analysis led to insights into rare IBMF diseases, including syndromes associated with DHX34, MDM4, RAD51, SRP54, and WIPF1. Our results provide an important population-based framework for the interpretation of LoF variant pathogenicity in rare and emerging IBMF syndromes.

Indexed as

Myelodysplastic SyndromesBiologyBone Marrow Failure DisordersCell Cycle ProteinsCytoskeletal ProteinsGenetic Association StudiesHumansIntracellular Signaling Peptides and ProteinsMutationProto-Oncogene ProteinsRNA HelicasesSignal Recognition ParticleCell Cycle ProteinsCytoskeletal ProteinsDHX34 protein, humanIntracellular Signaling Peptides and ProteinsMDM4 protein, humanProto-Oncogene ProteinsRNA HelicasesSignal Recognition ParticleSRP54 protein, humanWIPF1 protein, human

Identifiers

PMID33104793
PMCPMC7594375
OpenAlexW3093533018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.